Compare Novartis with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs VENUS REMEDIES - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS VENUS REMEDIES NOVARTIS/
VENUS REMEDIES
 
P/E (TTM) x 479.2 -1.0 - View Chart
P/BV x 27.8 0.1 39,085.7% View Chart
Dividend Yield % 1.6 0.0 -  

Financials

 NOVARTIS   VENUS REMEDIES
EQUITY SHARE DATA
    NOVARTIS
Mar-18
VENUS REMEDIES
Mar-18
NOVARTIS/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs758126 602.1%   
Low Rs57961 947.6%   
Sales per share (Unadj.) Rs228.4301.8 75.7%  
Earnings per share (Unadj.) Rs31.7-24.9 -127.6%  
Cash flow per share (Unadj.) Rs32.82.5 1,287.5%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.1293.3 101.3%  
Shares outstanding (eoy) m24.6912.34 200.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.90.3 944.8%   
Avg P/E ratio x21.1-3.8 -560.3%  
P/CF ratio (eoy) x20.436.7 55.5%  
Price / Book Value ratio x2.20.3 705.7%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,5051,154 1,430.5%   
No. of employees `0000.70.9 72.2%   
Total wages/salary Rs m1,445393 367.7%   
Avg. sales/employee Rs Th8,441.34,026.1 209.7%   
Avg. wages/employee Rs Th2,163.6425.0 509.1%   
Avg. net profit/employee Rs Th1,173.1-331.8 -353.6%   
INCOME DATA
Net Sales Rs m5,6393,724 151.4%  
Other income Rs m1,71823 7,636.9%   
Total revenues Rs m7,3573,747 196.4%   
Gross profit Rs m-63395 -15.8%  
Depreciation Rs m25338 7.5%   
Interest Rs m55354 15.6%   
Profit before tax Rs m1,575-275 -572.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m79232 2,505.1%   
Profit after tax Rs m784-307 -255.3%  
Gross profit margin %-1.110.6 -10.5%  
Effective tax rate %50.3-11.5 -437.8%   
Net profit margin %13.9-8.2 -168.6%  
BALANCE SHEET DATA
Current assets Rs m9,5222,638 361.0%   
Current liabilities Rs m3,2962,305 143.0%   
Net working cap to sales %110.48.9 1,234.6%  
Current ratio x2.91.1 252.4%  
Inventory Days Days37135 27.0%  
Debtors Days Days2846 61.3%  
Net fixed assets Rs m464,871 0.9%   
Share capital Rs m123123 100.0%   
"Free" reserves Rs m7,2133,496 206.3%   
Net worth Rs m7,3363,619 202.7%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m11,1057,509 147.9%  
Interest coverage x29.50.2 13,223.3%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.5 102.4%   
Return on assets %7.60.6 1,196.6%  
Return on equity %10.7-8.5 -126.0%  
Return on capital %22.21.6 1,404.8%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m610-   
Fx outflow Rs m3,630517 702.8%   
Net fx Rs m-3,570-517 691.1%   
CASH FLOW
From Operations Rs m1,610514 313.0%  
From Investments Rs m687-123 -558.1%  
From Financial Activity Rs m-2,677-387 691.4%  
Net Cashflow Rs m-3804 -9,038.1%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 0.2 1,111.1%  
FIIs % 1.6 0.6 275.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 66.4 32.4%  
Shareholders   41,647 20,121 207.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Oct 14, 2019 01:15 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS